At a glance
ClinicalIndex Comparison RecordN/ACompleted· 150 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Endothelial Function, Apolipoproteins, and Adiponectin Levels as Markers of Cardiovascular Before and After Liver Transplantation
In Brief
An observational study for Cirrhosis. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCirrhosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartJun 2011
Primary CompletionOct 2015
TodayJul 2026
First PostedFeb 21, 2011
Enrollment StartJun 1, 2011
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.4 years ago